Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pandion Therapeutics stock

Own Pandion Therapeutics stock in just a few minutes.

Pandion Therapeutics, Inc is a biotechnology business based in the US. Pandion Therapeutics shares (PAND) are listed on the NASDAQ and all prices are listed in US Dollars. Pandion Therapeutics employs 56 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Pandion Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PAND – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Pandion Therapeutics share price

Use our graph to track the performance of PAND stocks over time.

Pandion Therapeutics shares at a glance

Information last updated 2021-04-21.
52-week range$10.28 - $62.90
50-day moving average $56.73
200-day moving average $24.57
Wall St. target price$60.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Pandion Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pandion Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pandion Therapeutics financials

Revenue TTM $8.8 million
Gross profit TTM $8.8 million
Return on assets TTM -19.05%
Return on equity TTM -34.81%
Profit margin 0%
Book value N/A
Market capitalisation $1.8 billion

TTM: trailing 12 months

Shorting Pandion Therapeutics shares

There are currently 411,842 Pandion Therapeutics shares held short by investors – that's known as Pandion Therapeutics's "short interest". This figure is 57.1% down from 960,968 last month.

There are a few different ways that this level of interest in shorting Pandion Therapeutics shares can be evaluated.

Pandion Therapeutics's "short interest ratio" (SIR)

Pandion Therapeutics's "short interest ratio" (SIR) is the quantity of Pandion Therapeutics shares currently shorted divided by the average quantity of Pandion Therapeutics shares traded daily (recently around 748803.63636364). Pandion Therapeutics's SIR currently stands at 0.55. In other words for every 100,000 Pandion Therapeutics shares traded daily on the market, roughly 550 shares are currently held short.

However Pandion Therapeutics's short interest can also be evaluated against the total number of Pandion Therapeutics shares, or, against the total number of tradable Pandion Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pandion Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Pandion Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.04% of the tradable shares (for every 100,000 tradable Pandion Therapeutics shares, roughly 40 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pandion Therapeutics.

Find out more about how you can short Pandion Therapeutics stock.

Pandion Therapeutics share dividends

We're not expecting Pandion Therapeutics to pay a dividend over the next 12 months.

Pandion Therapeutics overview

Pandion Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprising an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies for the treatment of autoimmune diseases; PT001, a bifunctional molecule combining its PD-1 agonist effector with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM) to drive tissue-selective immunomodulation in the gastrointestinal tract; and PT002, a tethered bifunctional molecule that utilizes its IL-2 mutein effector module coupled with a MAdCAM-tether module to deliver the IL-2 mutein effector to the gastrointestinal tract where MAdCAM is expressed. It has a license and collaboration agreement with Astellas Pharma Inc. to discover and develop novel compounds for autoimmune diseases of the pancreas, including type 1 diabetes. The company was formerly known as Immunotolerance, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site